GlassScriptPhysician profile
Ashley M Vanwormer
NPI 1215279674
$2,030.71
in general payments reported to CMS, 2019-2025
25 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $127 · 2021: $538 · 2022: $363 · 2023: $194 · 2024: $187 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $420.91 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $198.20 | 2022-2025 | |
| Exeltis, USA INC. | $183.49 | 2020-2024 | Slynd |
| Astellas Pharma US INC | $146.25 | 2023-2025 | Veozah |
| Pfizer INC. | $137.51 | 2019-2025 | |
| Therapeuticsmd, INC. | $113.87 | 2019-2022 | |
| Organon LLC | $105.12 | 2021-2025 | Jada System |
| Myovant Sciences INC. | $77.86 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.84 | 2019-2021 | |
| Amgen INC. | $66.74 | 2019-2021 | |
| Millicent US INC | $57.03 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Evofem Biosciences, INC. | $54.65 | 2021-2023 | Phexxi |
| Scynexis, INC. | $52.28 | 2022 | |
| Merck Sharp & Dohme LLC | $50.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.59 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $43.58 | 2023 | Myfembree |
| Vertical Pharmaceuticals, LLC | $37.30 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.66 | 2022 | |
| Exact Sciences Corporation | $26.32 | 2025 | The Cologuard Plus Collection Kit |
| Sage Therapeutics, LLC | $23.58 | 2024 | |
| Amag Pharmaceuticals, INC. | $23.10 | 2019 | |
| Azurity Pharmaceuticals, INC. | $18.20 | 2023 | Adthyza |
| Agile Therapeutics, INC. | $17.74 | 2021 | |
| Duchesnay USA Incorporated | $17.44 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $17.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Vanwormer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.